Triflusal in the prevention of vascular dementia;Triflusal en la prevencion de la demencia vascular

Revista de Neurologia

Volumn 25, Issue 146, 1997, Pages 1525-1528

  Lopez Pousa S ^a   Mercadal Dalmau, J ^a   Marti Cuadros A M ^a   Vilalta Franch, J ^a   Lozano Gallego, M ^a  

^a HOSPITAL SANTA CATERINA   (Spain)

Author keywords

Anti aggregants; Risk factors; Triflusal; Vascular dementia

Indexed keywords

TRIFLUSAL; ANTITHROMBOCYTIC AGENT; SALICYLIC ACID DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; RISK FACTOR; THROMBOCYTE AGGREGATION; AGED; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AGED; CEREBROVASCULAR DISORDERS; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SALICYLATES;

EID: 0031241797     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Prencipe M, Ferreti C, Casini AR, Santini M, Giubilei F, Culasso F. Stroke, disability, and dementia. Results of a population survey. Stroke 1997; 28: 531-6.
2. Wilkinson PR, Wolfe CDA, Warburton FG, Rudd AG, Howard RS, Ross-Russell RW, et al. A long-term follow-up of stroke patients. Stroke 1997; 28: 507-12.
3. Lindsay J, Hébert R, Rockwood K. The Canadian study of health and aging. Risk factors for Vascular Dementia. Stroke 1997; 28: 526-30.
4. Breteler MMB, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: The Rotterdam Study. Neurology 1994; 44: 1246-52.
5. Awad IA, Johnson PC, Spetzler RF, Hodak JA. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly, II: Post mortem pathological correlations. Stroke 1986; 17: 1090-7.
6. Moroney JT, Bagiella E, Desmond DW, et al. Risk factors for incident dementia after stroke: Role of hypoxic and ischemic disorders. Stroke 1996; 27: 1283-9.
7. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994; 25: 318-27.
8. Elias MF, Wolf PA, D'Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: The Framingham study. Am J Epidemiol 1993; 138: 353-64.
9. Meyer JS, Judd BW, Tawaklna T, et al. Improved cognition after control of risk factors for multi-infarct dementia. JAMA 1986; 256: 2203-9.
10. Hachinski VD, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-7.
11. Rockwood K, Parhad I, Hachinski V, Erkinjuntti T, Rewcastle B, Kertesz A, et al. Diagnosis of vascular dementia: consortium of Canadian centres for clinical cognitive research consensus statement. Can J Neural Sci 1994; 21: 358-64.
12. Tatemichi TK, Desmond DW, Mayeux R, et al. Dementia after stroke: Baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992; 42: 1185-93.
13. Tatemichi TK, Paik M, Bagiella E, et al. Risk of dementia after stroke in a hospitalized cohort. Neurology 1994; 44: 1885-91.
14. Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B, et al. Dementia after first Stroke. Stroke 1996; 27: 1205-10.
15. Larson EB. Illness causing dementia in the very elderly. N Engl J Med 1993; 328: 203-5.
16. Skoog I. Risk factors for vascular dementia: A review. Dementia 1994; 5: 137-144.
17. N Engl J Med 1993; 328: 153-8.
18. López-Pousa S, Vilalta J, Llinàs J. Epidemiología de la demencia en España. Rev Gerontología (Número monográfico) 1995; 4: 28-33.
19. Hachinski V. Preventable senility: A call for action against the vascular dementias. Lancet 1992; 340: 645-8.
20. Starkstein SE, Sabe L, Vázquez S, Tesón A, Petracca G, Chemerinski E, et al. Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease. Stroke 1996; 27: 408-14.
21. Meyer JS, Rogers RL, McClintic K, Mortel KF. Controlled clinical trial of daily aspirin therapy in multi-infart dementia. Stroke 1988; 19: 148.
22. Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infart dementia: A pilot study. J Am Geriat Soc 1989; 37: 549-55.
23. Francía E, Marín A, García Rafanell J. Triflusal. Antithrombotic agent. Drugs Fut 1978; 3: 225-8.
24. Guiteras P, Altimiras J, Arís A, Augé JM, Bassons T, Bonal J, et al. Prevention of aorto-coronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: A randomized, double-blind, placebo-controlled trial. Eur Heart J 1989; 10: 159-67.
25. Plaza L, López-Bescós L, Martín-Jadraque L, Alegría E, Cruz-Fernández JM, Velasco J, et al. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: Results of a Spanish Multicenter Trial. Cardiology 1993; 82: 388-98.
26. Matías-Guiu J, Álvarez J, Galiano L, Codina A. The efficacy and safety of low-dose aspirin versus triflusal in long-term outcome of young Stroke patients. Neurology 1994; 44 (Suppl 2): S288.
27. Albors M, Castellarnau C, Vila L, Solá J, Rutilant ML. Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Rev Pharmacol Clin 1987; 4: 11-6.
28. Álvarez-Sabín A. Ácido acetilsalicílico y triflusal en la prevención del infarto cerebral aterotrombótico. Rev Neurol 1995; 23: 1091-5.
29. García Rafanell J, Planas JM, Puig Parellada P. Comparison of the inhibitory effects of acetylsalicylic acid and triflusal on enzymes related to thrombosis. Arch Int Pharmacodyn Ther 1979; 237: 343-50.
30. García Rafanell J, Ramis J, Gómez L, Fom J. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1986; 284: 155-65.
31. Castellarnau C, Sancho MJ, Vila L, Albors M, Rutilant ML. Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats. Prostagl Leukotr EFA 1988; 31: 83-9.
32. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrix H, Verma MS, et al. CAMDEX: A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
33. Llinás J, Vilalta J, López-Pousa S. CAMDEX: Adaptación y validación españolas. Barcelona: Áncora; 1991.
34. Roman GC, Tatemichi TX, Erkijuntti T, et al. Vascular Dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60.
35. Lobo A, Escobar V, Gómez Burgada F. 'Mini Examen Cognoscitivo' (Un test sencillo y práctico para la detección de alteraciones intelectuales). Actas Luso-Españolas Neurol-Psiquiatr 1979; 7: 189-202.
36. López-Pousa S, Mercadal J, Secades JJ, Lozano M, Martí AM, Vilalta J, et al. A method for quantifying cognitive impairment of vascular origin. Neurología: en prensa.
37. López-Pousa S, Lozano M, Mercadal J, Martí AM, Secades JJ, Vilalta J, et al. Una definición de deterioro cognitivo de origen vascular. Neurologia 1966; 11: 150.
38. Antiplatelet trialists collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-31.
39. Dyken ML. Meta-analysis in the assessment of therapy for stroke prevention. Cerebrovasc Dis 1992; 2 (Suppl 1): 35-40.
40. Antiplatelet trialists collaboration. Collaborative overview of randomized trials of antiplatelet therapy- 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
41. García E, Manríquez M, Orozco M, Pinilla-Fernández M, Prieto A, Reus JN, et al. Valoración clínica y analítica del triflusal, un antiagregante plaquetario, en pacientes geriátricos con alto riesgo de enfermedad tromboembólica. Estudio multicéntrico a largo plazo. Anal Geriatr Gerontol 1985; 2: 125-9.
42. Garay J, Flórez FJ, Roca F, Martínez C, Caballero JC, Guijarro JL, et al. ETPA: Estudio clinico multicéntrico para valorar la tolerancia de triflusal en la prevención del accidente vascular cerebral. Geriatrika 1993; 4: 63-9.
43. Blume J, Ruhlmann KU, De la Haye R, Rettig K. Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline. J Med 1992; 23: 417-32.
44. Folnegovic-Smalc V. European pentoxifylline multi-infart dementia trial (The EPMID study). Fourth meeting of the European Neurological Society. Barcelona, Spain, 1994, 25-29 June.
45. Cucinotta D, Aveni MA, Pedrazzi F, et al. Multicenter clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin. J Int Med Res 1992; 20: 136-49.
46. Grobe-Einsler R. Clinical aspects of nimodipine. Clin Neuropharmacol 1993; 16 (Suppl 1): S39-45.
47. Lozano M, Martí A, López-Pousa S, Vilalta J, Turón A. Eficiencia del Triflusal en demencias vasculares. Neurología 1996; 11: 143.